| Understanding tumour endothelial cell heterogeneity and function from single-cell omics Q Zeng, M Mousa, AS Nadukkandy, L Franssens, H Alnaqbi, FY Alshamsi, ... Nature Reviews Cancer 23 (8), 544-564, 2023 | 49 | 2023 |
| CD137L-DCs, potent immune-stimulators—history, characteristics, and perspectives Q Zeng, Y Zhou, H Schwarz Frontiers in immunology 10, 2216, 2019 | 27 | 2019 |
| CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotype B Dharmadhikari, E Nickles, Z Harfuddin, NDB Ishak, Q Zeng, A Bertoletti, ... Cancer Immunology, Immunotherapy 67, 893-905, 2018 | 24 | 2018 |
| The role of trogocytosis in immune surveillance of Hodgkin lymphoma Q Zeng, H Schwarz Oncoimmunology 9 (1), 1781334, 2020 | 15 | 2020 |
| Regulatory T cells inhibit T cell activity by downregulating CD137 ligand via CD137 trogocytosis K Luu, MV Patwardhan, Q Zeng, SL Wickström, A Lundqvist, H Schwarz Cells 10 (2), 353, 2021 | 12 | 2021 |
| Increased Akt-driven glycolysis is the basis for the higher potency of CD137L-DCs Q Zeng, K Mallilankaraman, H Schwarz Frontiers in Immunology 10, 868, 2019 | 11 | 2019 |
| Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy C Wang, Q Zeng, ZM Gül, S Wang, R Pick, P Cheng, R Bill, Y Wu, ... Cell 187 (11), 2690-2702. e17, 2024 | 10 | 2024 |
| Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors M Prasad, S Ponnalagu, Q Zeng, K Luu, SM Lang, HY Wong, MS Cheng, ... Cancer Immunology, Immunotherapy 71 (11), 2583-2596, 2022 | 7 | 2022 |
| CD137 ligand interacts with CD32a to trigger reverse CD137 ligand signaling Q Zeng, YM Soe, Y Lim, RM Sobota, H Schwarz Cellular & molecular immunology 17 (11), 1188-1189, 2020 | 6 | 2020 |
| Anti-CD137 cancer immunotherapy suppresses tumor growth B Dharmadhikari, Q Zeng, M Wu, H Schwarz Cancer research 78 (6), 1571-1571, 2018 | 6 | 2018 |
| Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting KY Lee, HY Wong, Q Zeng, J Le Lin, MS Cheng, CH Kuick, KTE Chang, ... Oncoimmunology 10 (1), 1877459, 2021 | 5 | 2021 |
| plasma factors for the differentiation of hodgkin’s lymphoma and diffused large B cell lymphoma and for monitoring remission Q Zeng, A Gupta, L Xin, M Poon, H Schwarz Journal of Hematology 8 (2), 47, 2019 | 5 | 2019 |
| Recent advances in exosome-based cancer immunotherapy Y Zhou, Q Zeng, H Schwarz J. Cancer Immunol. Ther. 1, 8-15, 2017 | 4 | 2017 |
| Circadian effects on vascular immunopathologies Q Zeng, VM Oliva, MÁ Moro, C Scheiermann Circulation Research 134 (6), 791-809, 2024 | 3 | 2024 |
| Circadian Rhythms in Anticancer Immunity: Mechanisms and Treatment Opportunities R Pick, C Wang, Q Zeng, ZM Gül, C Scheiermann Annual Review of Immunology 42 (1), 83-102, 2024 | | 2024 |
